MeiraGTx Holdings [MGTX] vs Cg Oncology [CGON] Detailed Stock Comparison
MeiraGTx Holdings
NASDAQ
Loading...
Cg Oncology
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: MeiraGTx Holdings wins in 6 metrics, Cg Oncology wins in 10 metrics, with 0 ties. Cg Oncology appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | MeiraGTx Holdings | Cg Oncology | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.75 | -18.47 | Cg Oncology |
| Price-to-Book Ratio | 19.41 | 2.74 | Cg Oncology |
| Debt-to-Equity Ratio | 244.35 | 0.15 | Cg Oncology |
| PEG Ratio | 9.75 | -14.24 | Cg Oncology |
| EV/EBITDA | -4.62 | -9.56 | Cg Oncology |
| Profit Margin (TTM) | 28.51% | 0.00% | MeiraGTx Holdings |
| Operating Margin (TTM) | -2,159.71% | -81,161.54% | MeiraGTx Holdings |
| Return on Equity | -216.14% | -16.58% | Cg Oncology |
| Return on Assets (TTM) | -37.28% | -12.85% | Cg Oncology |
| Free Cash Flow (TTM) | $-109.45M | $-78.95M | Cg Oncology |
| 1-Year Return | 65.06% | -17.45% | MeiraGTx Holdings |
| Price-to-Sales Ratio (TTM) | 18.85 | 2,917.75 | MeiraGTx Holdings |
| Enterprise Value | $675.76M | $1.28B | Cg Oncology |
| EV/Revenue Ratio | 19.58 | 1,939.26 | MeiraGTx Holdings |
| Gross Profit Margin (TTM) | 28.45% | N/A | N/A |
| Revenue per Share (TTM) | $0 | $0 | MeiraGTx Holdings |
| Earnings per Share (Diluted) | $-2.31 | $-1.50 | Cg Oncology |
| Beta (Stock Volatility) | 1.25 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
MeiraGTx Holdings vs Cg Oncology Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| MeiraGTx Holdings | -2.23% | -7.07% | 21.01% | 11.28% | 22.71% | 25.84% |
| Cg Oncology | 3.34% | 2.24% | 3.50% | -0.11% | -10.75% | -7.11% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| MeiraGTx Holdings | 65.06% | -23.77% | -42.83% | -47.40% | -47.40% | -47.40% |
| Cg Oncology | -17.45% | -23.18% | -23.18% | -23.18% | -23.18% | -23.18% |
Performance & Financial Health Analysis: MeiraGTx Holdings vs Cg Oncology
| Metric | MGTX | CGON |
|---|---|---|
| Market Information | ||
| Market Cap | $650.56M | $1.93B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 425,544 | 1,041,413 |
| 90 Day Avg. Volume | 506,531 | 910,244 |
| Last Close | $7.89 | $26.91 |
| 52 Week Range | $3.85 - $8.98 | $14.80 - $40.47 |
| % from 52W High | -12.14% | -33.51% |
| All-Time High | $30.23 (Jul 08, 2019) | $50.23 (Feb 12, 2024) |
| % from All-Time High | -73.90% | -46.43% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 1.76% | -0.90% |
| Quarterly Earnings Growth | 1.76% | -0.90% |
| Financial Health | ||
| Profit Margin (TTM) | 0.29% | 0.00% |
| Operating Margin (TTM) | -21.60% | -811.62% |
| Return on Equity (TTM) | -2.16% | -0.17% |
| Debt to Equity (MRQ) | 244.35 | 0.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.42 | $9.25 |
| Cash per Share (MRQ) | $0.83 | $9.03 |
| Operating Cash Flow (TTM) | $-104,582,000 | $-81,978,000 |
| Levered Free Cash Flow (TTM) | $-53,246,124 | $-57,183,624 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: MeiraGTx Holdings vs Cg Oncology
| Metric | MGTX | CGON |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.75 | -18.47 |
| Forward P/E | 9.75 | -14.24 |
| PEG Ratio | 9.75 | -14.24 |
| Price to Sales (TTM) | 18.85 | 2,917.75 |
| Price to Book (MRQ) | 19.41 | 2.74 |
| Market Capitalization | ||
| Market Capitalization | $650.56M | $1.93B |
| Enterprise Value | $675.76M | $1.28B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 19.58 | 1,939.26 |
| Enterprise to EBITDA | -4.62 | -9.56 |
| Risk & Other Metrics | ||
| Beta | 1.25 | N/A |
| Book Value per Share (MRQ) | $0.42 | $9.25 |
Financial Statements Comparison: MeiraGTx Holdings vs Cg Oncology
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MGTX | CGON |
|---|---|---|
| Revenue/Sales | $1.93M | $52,000 |
| Cost of Goods Sold | $1.38M | N/A |
| Gross Profit | $548,000 | N/A |
| Research & Development | $32.78M | $27.47M |
| Operating Income (EBIT) | $-41.60M | $-42.20M |
| EBITDA | $-37.54M | $-42.18M |
| Pre-Tax Income | $-39.98M | $-34.45M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-39.98M | $-34.45M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MGTX | CGON |
|---|---|---|
| Cash & Equivalents | $66.52M | $41.47M |
| Total Current Assets | $79.89M | $701.19M |
| Total Current Liabilities | $52.37M | $22.64M |
| Long-Term Debt | $77.58M | $781,000 |
| Total Shareholders Equity | $33.10M | $704.76M |
| Retained Earnings | $-742.00M | $-252.43M |
| Property, Plant & Equipment | $133.48M | $1.30M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MGTX | CGON |
|---|---|---|
| Operating Cash Flow | $-29.44M | $-28.85M |
| Capital Expenditures | $-1.71M | $-16,000 |
| Free Cash Flow | $-38.54M | $-29.29M |
| Debt Repayment | N/A | $0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MGTX | CGON |
|---|---|---|
| Shares Short | 3.55M | 10.78M |
| Short Ratio | 6.49 | 12.77 |
| Short % of Float | 0.07% | 0.15% |
| Average Daily Volume (10 Day) | 425,544 | 1,041,413 |
| Average Daily Volume (90 Day) | 506,531 | 910,244 |
| Shares Outstanding | 78.40M | 76.15M |
| Float Shares | 36.65M | 61.13M |
| % Held by Insiders | 0.24% | 0.01% |
| % Held by Institutions | 0.60% | 1.06% |
Dividend Analysis & Yield Comparison: MeiraGTx Holdings vs Cg Oncology
| Metric | MGTX | CGON |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |